Search results
Results from the WOW.Com Content Network
The bacteriophages used for cloning are the λ phage and M13 phage. [13] There is an upper limit on the amount of DNA that can be packed into a phage (a maximum of 53 kb), therefore to allow foreign DNA to be inserted into phage DNA, phage cloning vectors may need to have some non-essential genes deleted, for example the genes for lysogeny ...
Cosmids are predominantly plasmids with a bacterial oriV, an antibiotic selection marker and a cloning site, but they carry one, or more recently two, cos sites derived from bacteriophage lambda. Depending on the particular aim of the experiment, broad host range cosmids, shuttle cosmids or 'mammalian' cosmids (linked to SV40 oriV and mammalian ...
Phage therapy, viral phage therapy, or phagotherapy is the therapeutic use of bacteriophages for the treatment of pathogenic bacterial infections. [ 1 ] [ 2 ] [ 3 ] This therapeutic approach emerged at the beginning of the 20th century but was progressively replaced by the use of antibiotics in most parts of the world after the Second World War .
After eight weeks of phage therapy, in conjunction with 12 weeks of antibiotics, no evidence of Acinetobacter baumannii was found in Patterson's body following June 6, 2016. [ 5 ] [ 8 ] After positive media attention from Patterson's phage therapy, [ 9 ] [ 10 ] [ 11 ] Schooley and Strathdee began to receive phage therapy requests from around ...
The George Eliava Institute of Bacteriophage, Microbiology and Virology [1] (aka Tbilisi Institute) has been active since the 1930s in the field of phage therapy, which is used to combat microbial infection (cf. antibiotic-resistant strains).
The integration of phage λ takes place at a special attachment site in the bacterial and phage genomes, called att λ. The sequence of the bacterial att site is called attB, between the gal and bio operons, and consists of the parts B-O-B', whereas the complementary sequence in the circular phage genome is called attP and consists of the parts ...
Locus Biosciences is a clinical-stage pharmaceutical company, founded in 2015 and based in Research Triangle Park, North Carolina. [2] Locus develops phage therapies based on CRISPR–Cas3 gene editing technology, as opposed to the more commonly used CRISPR-Cas9, delivered by engineered bacteriophages. [5]
Bacteriophages and Biofilms: Ecology, Phage Therapy, Plaques. Nova Science Publishers , Hauppauge, New York. Partial online version is also available, constituting effectively a " first edition ".